12 Nov 2025 | 3 Mins Read
Motilal Oswal sees Rs 240 target for Piramal Pharma
Flipitmoney
Piramal Pharma Ltd. delivered in-line revenue for 2QFY62 but missed on EBITDA/PAT due to higher operational costs. Despite impacted CDMO sales, the company is seeing improved biotech funding, leading to order inflows. The target price is INR240, with 18x EV/EBITDA for CDMO, 12x for CHG, and 13x for ICH.